Search clinical trials for: peginterferon alfa

Total 10677 results

Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Hepatitis B, Chronic

Italy
Hoffmann-La Roche

Completed

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China, Korea, Republic of, Taiwan, Germany, United States, Singapore, Switzerland, Canada, Puerto Rico, Thailand, Israel, France, New Zealand, Poland, United Kingdom, Brazil, Australia
Hoffmann-La Roche

Withdrawn

A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

Hepatitis B, Chronic
University of Utah
Schering-Plough

Terminated

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Gastrointestinal Stromal Tumors | Solid Tumors | Cancer Brain

United States
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hepatitis B, Chronic

New Zealand
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Chronic Hepatitis B

China
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb

Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Hepatitis C Virus Genotype 4 Infection

France
Hoffmann-La Roche

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (IMPROVE)

Hepatitis C, Chronic

Canada, United States
Debiopharm International SA

Terminated

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Hepatitis C

United States
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Withdrawn

Asthma Clinical Research Network (ACRN)

Lung Diseases | Asthma

United States
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy
University of Kansas Medical Center

Completed

Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer

Prostate Cancer

United States
Hoffmann-La Roche

Completed

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Renal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant Melanoma

Canada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)

Hepatitis C

Taiwan
Hoffmann-La Roche

Terminated

An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients

Hepatitis C, Chronic

Hungary
Hoffmann-La Roche

Completed

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Hepatitis C, Chronic

Brazil
AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)

Completed

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Polycythemia Vera

Spain, Belgium, Austria, Italy, Bulgaria, Czech Republic, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection

Chronic Hepatitis b

China
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

Italy
Hoffmann-La Roche

Completed

A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Israel
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, Germany, United States, Canada, Austria, Puerto Rico
Hoffmann-La Roche

Terminated

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues

Hepatitis B, Chronic

Poland
Hoffmann-La Roche

Completed

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

Carcinoma, Hepatocellular

China, Thailand, Taiwan
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B

Hepatitis B, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic
Hoffmann-La Roche

Terminated

An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)

Hepatitis D, Chronic

Romania
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

China
Hoffmann-La Roche

Completed

A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265

Hepatitis B, Chronic

China
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Hepatitis C, Chronic

Taiwan, Korea, Republic of, Thailand
Hoffmann-La Roche

Completed

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

Germany, Austria, Hungary, Romania, Spain, Poland
Hoffmann-La Roche
Major Science and Technology Special Project of China Eleventh Five-year

Completed

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

Hepatitis B, Chronic

China
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Hepatitis C, Chronic

United States, Canada, Australia, France, Germany, Austria, Italy
Hoffmann-La Roche

Completed

Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Hepatitis B, Chronic

Italy
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Hepatitis B, Chronic

Hong Kong, China
Hoffmann-La Roche

Withdrawn

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)

Hepatitis B, Chronic

Greece
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Withdrawn

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

Bulgaria
Hoffmann-La Roche

Completed

An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Poland
Hoffmann-La Roche

Completed

ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Hepatitis B, Chronic

Turkey
Hoffmann-La Roche

Completed

An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

France
Hoffmann-La Roche

Completed

A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Hepatitis C, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Hepatitis C, Chronic

France, Spain, United States, Germany, Canada, Australia, Austria, United Kingdom, Puerto Rico, Italy

3

Subscribe